156 related articles for article (PubMed ID: 21123974)
1. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab.
Kurokawa T; Kaya H; Yoshida T
J Clin Exp Hematop; 2010; 50(2):159-62. PubMed ID: 21123974
[TBL] [Abstract][Full Text] [Related]
2. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
[No Abstract] [Full Text] [Related]
3. The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience.
Hardak E; Oren I; Dann EJ; Yigla M; Faibish T; Rowe JM; Avivi I
Acta Haematol; 2012; 127(2):110-4. PubMed ID: 22178955
[TBL] [Abstract][Full Text] [Related]
4. Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy.
Kim T; Choi SH; Kim SH; Jeong JY; Woo JH; Kim YS; Sung H; Kim MN; Yoon DH; Suh C; Lee SO
Ann Hematol; 2013 Jan; 92(2):231-8. PubMed ID: 23053189
[TBL] [Abstract][Full Text] [Related]
5. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma.
Katsuya H; Suzumiya J; Sasaki H; Ishitsuka K; Shibata T; Takamatsu Y; Tamura K
Leuk Lymphoma; 2009 Nov; 50(11):1818-23. PubMed ID: 19863173
[TBL] [Abstract][Full Text] [Related]
6. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
[TBL] [Abstract][Full Text] [Related]
7. A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?
Tadmor T; McLaughlin P; Polliack A
Leuk Lymphoma; 2010 May; 51(5):737-8. PubMed ID: 20367567
[No Abstract] [Full Text] [Related]
8. The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis.
Isidori A; Merli F; Angrilli F; Ferrara F; Alesiani F; Visani G
Leuk Lymphoma; 2011 Jan; 52(1):148-9. PubMed ID: 21067442
[No Abstract] [Full Text] [Related]
9. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy.
Barreto JN; Ice LL; Thompson CA; Tosh PK; Osmon DR; Dierkhising RA; Plevak MF; Limper AH
Am J Hematol; 2016 Nov; 91(11):1113-1117. PubMed ID: 27472910
[TBL] [Abstract][Full Text] [Related]
10. Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.
Hashimoto K; Kobayashi Y; Asakura Y; Mori M; Azuma T; Maruyama D; Kim SW; Watanabe T; Tobinai K
Leuk Lymphoma; 2010 Oct; 51(10):1816-21. PubMed ID: 20919860
[TBL] [Abstract][Full Text] [Related]
11. Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab.
Chang H; Yeh HC; Su YC; Lee MH
J Chin Med Assoc; 2008 Nov; 71(11):579-82. PubMed ID: 19015057
[TBL] [Abstract][Full Text] [Related]
12. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone.
Kamel S; O'Connor S; Lee N; Filshie R; Nandurkar H; Tam CS
Leuk Lymphoma; 2010 May; 51(5):797-801. PubMed ID: 20367135
[TBL] [Abstract][Full Text] [Related]
13. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome.
Sato M; Ito S; Ogura M; Kamei K; Miyairi I; Miyata I; Higuchi M; Matsuoka K
Pediatr Nephrol; 2013 Jan; 28(1):145-9. PubMed ID: 22948319
[TBL] [Abstract][Full Text] [Related]
14. Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP.
Lee JY; Kang M; Suh KJ; Kim JW; Kim SH; Kim JW; Kim YJ; Song KH; Kim ES; Kim HB; Lee KW; Kim JH; Bang SM; Lee JS; Lee JO
Mycoses; 2021 Jan; 64(1):60-65. PubMed ID: 32970331
[TBL] [Abstract][Full Text] [Related]
15. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.
Kolstad A; Holte H; Fosså A; Lauritzsen GF; Gaustad P; Torfoss D
Haematologica; 2007 Jan; 92(1):139-40. PubMed ID: 17229653
[TBL] [Abstract][Full Text] [Related]
16. Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review.
Jiang XQ; Fang L; Mei XD; Wang XJ; Bao MH
J Thorac Dis; 2013 Aug; 5(4):E162-6. PubMed ID: 23991330
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature.
Yokoyama H; Watanabe T; Maruyama D; Kim SW; Kobayashi Y; Tobinai K
Int J Hematol; 2008 Nov; 88(4):443-447. PubMed ID: 18855101
[TBL] [Abstract][Full Text] [Related]
18. [Rash, fever, eosinophilia and elevated liver enzymes. DRESS syndrome (drug reaction or rash with eosinophilia and systemic symptoms)].
Derungs A; Rätz Bravo AE; Kummer O
Praxis (Bern 1994); 2010 Jun; 99(13):767-77; quiz 776. PubMed ID: 20571998
[TBL] [Abstract][Full Text] [Related]
19. [Pneumocystis pneumonia prophylaxis with low-dose trimethoprim/sulfamethoxazole during rituximab-containing chemotherapy].
Shimizu R; Sakemura R; Iwata S; Hayakawa H; Miyao K; Kajiguchi T
Rinsho Ketsueki; 2019; 60(5):365-371. PubMed ID: 31167996
[TBL] [Abstract][Full Text] [Related]
20. Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis.
Liu C; Zhang X; Zhu Y; Wei J; Ye X; Yang C; Tong H; Mai W; Yang M; Qian J; Mao L; Meng H; Jin J; Yu W
Ann Hematol; 2023 Sep; 102(9):2387-2395. PubMed ID: 37278748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
